Aprea Therapeutics Inc (APRE)

Apr 17, 2025

Century Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy Advances - MyChesCo

Apr 17, 2025

Apr 17, 2025

APRE stock touches 52-week low at $1.5 amid market challenges - Investing.com Australia

Apr 17, 2025

Apr 17, 2025

Adicet Bio Strengthens Board with Ex-Johnson & Johnson VP: Strategic Move for Cell Therapy Pioneer - Stock Titan

Apr 17, 2025

Apr 10, 2025

Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion - MSN

Apr 10, 2025

Apr 10, 2025

Aprea Therapeutics Advances ACESOT-1051 Clinical Trial with Key Patient Dosing - MSN

Apr 10, 2025

Apr 08, 2025

TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve

Apr 08, 2025

Apr 04, 2025

APRE stock touches 52-week low at $1.74 amid market challenges - Investing.com

Apr 04, 2025

Apr 04, 2025

Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock By Investing.com - Investing.com India

Apr 04, 2025

Apr 04, 2025

Aprea Therapeutics President/CEO Gilad Oren Acquires 5,500 Shares - TradingView

Apr 04, 2025

Apr 04, 2025

Aprea Therapeutics CEO Gilad Oren acquires $10,110 in stock - Investing.com

Apr 04, 2025

Apr 03, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Apr 03, 2025

Apr 01, 2025

Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial - Yahoo

Apr 01, 2025

Apr 01, 2025

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March - Defense World

Apr 01, 2025

Mar 31, 2025

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial - TradingView

Mar 31, 2025

Mar 31, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 31, 2025

Mar 30, 2025

What is Wedbush’s Estimate for APRE FY2025 Earnings? - The AM Reporter

Mar 30, 2025

Mar 29, 2025

Brokers Issue Forecasts for APRE FY2025 Earnings - Defense World

Mar 29, 2025

Mar 28, 2025

Aprea Therapeutics Reports 2024 Financial Results and Updates on Clinical Innovations - MSN

Mar 28, 2025

Mar 28, 2025

What is Wedbush’s Estimate for APRE FY2029 Earnings? - Defense World

Mar 28, 2025

Mar 27, 2025

APRE stock touches 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 27, 2025

APRE stock touches 52-week low at $2.15 amid market challenges - Investing.com India

Mar 27, 2025

Mar 26, 2025

Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush - Defense World

Mar 26, 2025

Mar 26, 2025

Aprea Therapeutics Advances Cancer Trials Amid Financial Progress - TipRanks

Mar 26, 2025

Mar 25, 2025

Aprea Therapeutics repots Q4 EPS (49c) vs. (92c) last year - TipRanks

Mar 25, 2025

Mar 25, 2025

Aprea Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 25, 2025

APREA THERAPEUTICS Earnings Results: $APRE Reports Quarterly Earnings - Nasdaq

Mar 25, 2025

Mar 25, 2025

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Mar 25, 2025

Mar 25, 2025

Chronic Myeloid Leukemia Pipeline: Driving Innovation with 25+ - openPR.com

Mar 25, 2025

Mar 21, 2025

Windtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI - MyChesCo

Mar 21, 2025

Mar 18, 2025

Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MyChesCo

Mar 18, 2025

Mar 18, 2025

Aprea Therapeutics (APRE) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 18, 2025

Mar 13, 2025

Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research - MyChesCo

Mar 13, 2025

Mar 12, 2025

MD Anderson to explore Aprea’s WEE1 kinase inhibitor for HNSCC - BioWorld Online

Mar 12, 2025

Mar 11, 2025

Aprea Therapeutics partners with MD Anderson for cancer study - Investing.com India

Mar 11, 2025

Mar 11, 2025

Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc) - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Aprea Therapeutics partners with MD Anderson for cancer study By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 11, 2025

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) - The Manila Times

Mar 11, 2025

Mar 07, 2025

Aprea Therapeutics to Showcase Expertise at Maxim Healthcare Virtual Summit - MSN

Mar 07, 2025

Mar 03, 2025

Aprea Therapeutics to Showcase Oncology Advances at Barcelona Symposium - MSN

Mar 03, 2025

Feb 26, 2025

Head-To-Head Comparison: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aprea Therapeutics (NASDAQ:APRE) - Defense World

Feb 26, 2025

Feb 12, 2025

Insider Buyers Lose US$92k As Aprea Therapeutics Sheds US$3.2m - Simply Wall St

Feb 12, 2025

Feb 07, 2025

Aprea Therapeutics Strengthens Patent Portfolio to Advance Oncology Innovation - MSN

Feb 07, 2025